ZYME Zymeworks Inc. Insider Trading

CEO Kenneth Galbraith sold 30,424 shares of ZYME at $22.67 on 2026-01-12, reducing holdings to 226,842 shares.

Kenneth Galbraith (Chair & CEO) sold 30,424 shares at $22.67, reducing his stake by 11.8% from 257,266 shares to 226,842 shares. This is the insider's fourth consecutive sale in a 7-day window (three prior sales between 2026-01-05 and 2026-01-12), suggesting a deliberate program of share reduction. His cross-ticker track record shows 5 prior sells with a 90-day well-timed rate of 100.00%, indicating a historical pattern of selling before declines; at ZYME specifically, his 2 prior measurable sales (both on 2025-01-06) each showed -26.6% 90-day returns, confirming sell-side timing accuracy at this ticker. The company reported $-19.6M net income against $27.6M quarterly revenue and posted only 0.4% annual revenue growth, underperforming despite a 27.0% 90-day stock price gain from $18.16 to $23.16; the stock is now 16.2% below its 52-week high and down 9.1% over 30 days. Sustained insider selling by the CEO against a backdrop of profitability challenges and deteriorating 30-day momentum warrants attention.

CEO Kenneth Galbraith sold 54,343 shares (54.3K shares) at $25.10 for $1,363,840.83 in 2 transactions, reducing holdings 21.9%.

Kenneth Galbraith, Chair & CEO of Zymeworks Inc., executed 2 separate sales totaling 54,343 shares at $25.10 on 2026-01-05, reducing his holdings from 247,609 shares to 193,266 shares. At the transacted price of $25.10, this represents a substantial reduction in his position during a period when the stock trades near recent highs (current $25.48 is -7.8% from the 52-week high of $27.62). Notably, his cross-ticker track record shows 100.00% well-timed sell rate with an average 90-day post-sale return of -26.6%, and his prior trades at ZYME also demonstrate well-timed exits (2 of 2 prior sells showed negative 90-day returns). However, the company faces headwinds: net income is $-19,602,000.00 (deeply unprofitable), annual revenue growth is only +0.4%, and the 90-day stock performance of +54.4% contrasts sharply with the underlying weak fundamentals. This sale by the CEO occurs as the stock has appreciated significantly in the recent period despite operational losses, potentially warranting investor scrutiny of valuation sustainability.

ZYME Chair & CEO Galbraith sold 47,528 shares at $27.02; 2 prior sells at this ticker both well-timed; stock now at 52-week high amid unprofitable fundamentals.

Kenneth Galbraith, Chair & CEO of Zymeworks, sold 47,528 shares on 2025-12-22 at $27.02, reducing his holdings by 26.3% from 180,803 to 133,275 shares. The sale occurred with the stock trading at its 52-week high of $27.62 after a 15.0% gain over the prior 30 days and 68.8% over 90 days. Notably, Galbraith's prior 2 open-market sales at ZYME both produced negative 90-day returns, with a 100% well-timed rate at that ticker—meaning he has consistently sold before subsequent declines. Against this backdrop, the company remains unprofitable (full-year net income was negative, latest quarterly net income was $-19,602,000) with minimal annual revenue growth at 0.4%, creating a divergence between his demonstrated historical timing pattern and current valuation momentum. This substantial insider reduction at a 52-week peak warrants attention to whether the established pattern of sales preceding declines will hold.

Director EcoR1 Capital bought 55,421 shares (55.4K) at $11.47 avg in May; holding now 17.88M shares amid ZYME losses.

EcoR1 Capital, a director of Zymeworks, executed 2 separate purchases totaling 55,421 shares for $635,585.71 in mid-May 2025 at an average price of $11.47. The current price of $11.82 is -32.1% from the 52-week high of $17.40, placing the transaction near recent lows. EcoR1's prior 5 purchases at ZYME all showed positive 30-day returns (ranging from +1.6% to +16.0%), though longer-term outcomes remain unmeasurable. However, the company's fundamentals present a headwind: Zymeworks reported a net loss of $-22,636,000.00 against quarterly revenue of $27,110,000.00, with annual revenue growth of just +0.4%, indicating persistent unprofitability and minimal growth. The director's continued accumulation—now holding 17.88M shares (+0.3% net increase)—occurs amid deteriorating financial metrics, not strength.

EcoR1 Capital (Director) bought 128,713 shares over 2 days for $1,456,407.88; stock down 33.7% YTD amid operating losses.

EcoR1 Capital purchased 128,713 shares across 2 separate transactions on April 16–17, 2025, at a blended average price of $11.32, increasing its holdings from 17.70M to 17.83M shares. This acquisition occurs while ZYME trades 33.7% below its 52-week high and the company is structurally unprofitable, reporting $-29.8M net income against $16.0M quarterly revenue. The timing is notable: EcoR1 has already executed 5 buys at ZYME within the preceding 16 days (March 31 through April 4), suggesting sustained accumulation. However, EcoR1's cross-ticker track record shows a 0.00% win rate on 20 prior open-market buys with an average 90-day return of -19.2%, indicating a pattern of poor buy-timing execution. The consistent purchasing despite widening losses and steep price declines, coupled with this insider's historically unsuccessful buy timing, leaves the signal ambiguous—whether this reflects conviction in turnaround potential or continued execution challenges cannot be determined from the data alone.

EcoR1 Capital director bought 317,208 shares at blended $11.42; stock now $10.43, down 40.1% from 52-week high

EcoR1 Capital, LLC acquired 317,208 shares across two separate transactions on 2025-04-03 and 2025-04-04 at prices of $11.84 and $11.17, representing a blended average of $11.42 and a total outlay of $3,623,970.36. The purchase increased the director's holdings by 1.8%, to 17,699,774 shares post-transaction. The timing of this purchase occurs against a backdrop of significant price deterioration: the stock has declined 40.1% from its 52-week high of $17.40 and is currently trading at $10.43, with losses of 13.1% over the prior 30 days and 27.1% over 90 days. The company's fundamentals show operational strain, with net income of $-29,850,000 (negative over the latest full fiscal year) against quarterly revenue of $16,000,000, though the director's cross-ticker track record shows an average 30-day return of +7.8% on 20 prior buy transactions. At the same ticker (ZYME), the director executed 5 prior buys dating back to 2025-03-25, none yet reaching 90-day measurement windows, establishing a rapid accumulation pattern within a compressed timeframe during a period of sharp stock decline.

Director EcoR1 Capital acquired 127,415 shares across 3 open-market transactions (Mar 31–Apr 2) at $11.75 blended avg; stock down 31.5% from 52-week high amid losses.

EcoR1 Capital, a director at Zymeworks, executed 3 separate purchases totaling 127,415 shares for $1,497,322.33 between March 31 and April 2, 2025, at prices ranging from $11.60 to $11.85. The activity comes as Zymeworks stock trades at $11.92, down 31.5% from its 52-week high of $17.40 and off 19.4% over the past 90 days. Fundamentally, the company is unprofitable—recording net income of $-29,850,000.00 against quarterly revenue of $16,000,000.00—and annual revenue growth has decelerated to +0.4%. The director's cross-ticker track record shows a 0.00% win rate on buys at the 90-day mark with an average 90d return of −19.4%, a pattern consistent with recent market weakness in this holding. While the director's prior purchases at ZYME (5 trades dating March 20–26) remain outcome-unmeasurable, the timing of these three latest buys near depressed price levels—coinciding with the stock's decline from recent highs—occurred in a context of persistent unprofitability and minimal growth, raising questions about whether the purchases reflect conviction in a turnaround or simply accumulation at lower entry points during a broader downturn.

EcoR1 Capital, LLC (Director) bought 97,349 shares (97.3K shares) in ZYME across 2 transactions for $1,227,309.18 ($1.2M) at blended $12.61, amid 28.1% decline from 52-week high.

EcoR1 Capital, LLC executed 2 separate purchases totaling 97,349 shares for $1,227,309.18 ($1.2M) on March 25–26, 2025, at an average price of $12.61 per share. This buying follows four consecutive prior purchases at ZYME within the preceding week (March 18–24), suggesting sustained accumulation. The timing coincides with material price weakness: the stock is -28.1% from its 52-week high and down 7.8% over the prior 30 days. ZYME is unprofitable (net income $-29,850,000.00 for the latest full year) on minimal revenue growth (+0.4% year-over-year), so the director's continued buying into deteriorating fundamentals and falling price merits investor attention. EcoR1's cross-ticker track record shows a 5.2% average 30-day return on prior buys, but this company-specific trading pattern is new territory with no measurable outcomes yet.

EcoR1 Capital director buys 127,198 shares in ZYME across 3 trades (3/20-3/24) for $1,643,247.97 at $12.92 avg.

EcoR1 Capital executed three separate purchases totaling 127,198 shares for $1,643,247.97 over a four-day window (March 20–24), adding 0.7% to its 17.03M-share position at blended average price of $12.92. The timing occurs as ZYME trades 25.0% below its 52-week high and down 9.3% in the past 30 days, while the company reported $16.0M quarterly revenue but a $-29.8M net loss, reflecting unprofitability. EcoR1's cross-ticker buy track record shows a +4.4% average 30-day return across 20 prior transactions, though the five most recent ZYME purchases (March 12–19) remain too recent to measure outcomes and do not yet show a measurable pattern at this ticker. The filing itself presents a material acquisition by a significant director, but the accumulation occurs amid price weakness and negative recent momentum without yet demonstrating whether this represents a repeated conviction pattern at ZYME or routine incremental position management.

EcoR1 Capital (Director) bought 228,463 shares at blended $12.55 across three days (totaling $2.9M)

EcoR1 Capital executed 3 separate purchases totaling 228,463 shares for $2,866,552.72 at prices ranging from $12.23 to $12.65 on March 17–19, 2025, increasing its stake to 17,030,604 shares. The timing is notable: these purchases came immediately after similar buys on March 11–13, establishing a pattern of heavy accumulation over a one-week window. At the current price of $12.79, the stock is -26.5% from its 52-week high and has declined -14.8% over the last 30 days, yet this insider has continued to add. The company is unprofitable (net income of $-29,850,000 in the latest quarter) with minimal revenue growth of +0.4% year-over-year, so this sustained accumulation during a period of stock weakness and operational losses merits close attention. The insider's cross-ticker track record shows an average 30-day return of +4.2% on 19 prior buys, though same-ticker outcomes at ZYME remain largely unmeasurable for recent transactions.